Roche to showcase 20-medicines at ASCO 2017

12 May 2017

No fewer than 20 medicines from Swiss pharma giant Roche (SIX: ROG) will be included in more than 190 abstracts being presented at next month’s 2017 American Society of Clinical Oncology (ASCO) Annual Meeting.

The company bills itself as a ‘world leader in innovative cancer drugs’ and this position is cemented by the volume of presentations that there will be on its different oncology assets at the world’s largest oncology conference.

Pivotal results for Perjeta (pertuzumab) and Alecensa (alectinib) showing improvements upon standards of care will be among the data presented.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK